Taken together, our results suggest that frontline ICIs offer a viable alternative to targeted therapy in individuals with Class I BRAF-mutant NSCLC, particularly in those whose PD-L1 expression is elevated. This evidence concerns the gene CD274 and non-small cell lung carcinoma.